



US008889159B2

(12) **United States Patent**
Cleary et al.

(10) **Patent No.:** **US 8,889,159 B2**
(45) **Date of Patent:** ***Nov. 18, 2014**

(54) **COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS**

- (71) Applicant: **Gilead Pharmasset LLC**, Foster City, CA (US)
- (72) Inventors: **Darryl G. Cleary**, Chapel Hill, NC (US); **Charles J. Reynolds**, Greenville, NC (US); **Miriam Michelle Berrey**, Durham, NC (US); **Robert G. Hindes**, Skillman, NJ (US); **William T. Symonds**, San Francisco, CA (US); **Adrian S. Ray**, Redwood City, CA (US); **Hongmei Mo**, Palo Alto, CA (US); **Christy M. Hebner**, Belmont, CA (US); **Reza Oliyai**, Burlingame, CA (US); **Vahid Zia**, San Carlos, CA (US); **Dimitrios Stefanidis**, Mountain View, CA (US); **Rowchanak Pakdaman**, San Carlos, CA (US); **Melissa Jean Casteel**, Burlingame, CA (US)

(73) Assignee: **Gilead Pharmasset LLC**, Foster City, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/686,664**

(22) Filed: **Nov. 27, 2012**

(65) **Prior Publication Data**

US 2013/0136776 A1 May 30, 2013

Related U.S. Application Data

(63) Continuation-in-part of application No. PCT/US2012/055621, filed on Sep. 14, 2012, and a continuation-in-part of application No. 13/661,509, filed on Oct. 26, 2012.

(60) Provisional application No. 61/564,500, filed on Nov. 29, 2011, provisional application No. 61/707,459, filed on Sep. 28, 2012.

- (51) **Int. Cl.**
A61K 47/10 (2006.01)
C07H 19/04 (2006.01)
A61K 31/513 (2006.01)
A61K 31/675 (2006.01)
A61K 31/4196 (2006.01)

(52) **U.S. Cl.**
CPC *A61K 31/675* (2013.01); *A61K 31/513* (2013.01); *A61K 31/4196* (2013.01)
USPC **424/400**; 514/86; 536/26.8

(58) **Field of Classification Search**

(56) **References Cited**

U.S. PATENT DOCUMENTS

- 3,798,209 A 3/1974 Witkowski et al.
- 3,852,267 A 12/1974 Meyer, Jr. et al.
- RE29,835 E 11/1978 Witkowski et al.
- 4,814,477 A 3/1989 Wijnberg et al.
- 4,957,924 A 9/1990 Beauchamp
- 5,026,687 A 6/1991 Yarchoan et al.
- 5,118,820 A 6/1992 Hertel
- 5,149,794 A 9/1992 Yatvin et al.
- 5,157,027 A 10/1992 Biller et al.
- 5,192,549 A 3/1993 Barenolz et al.
- 5,194,654 A 3/1993 Hostetler et al.
- 5,210,015 A 5/1993 Gelfand et al.
- 5,223,263 A 6/1993 Hostetler et al.
- 5,256,641 A 10/1993 Yatvin et al.
- 5,256,798 A 10/1993 Chou et al.
- 5,372,808 A 12/1994 Blatt et al.
- 5,376,380 A 12/1994 Kikuchi et al.
- 5,405,598 A 4/1995 Schinazi et al.
- 5,411,947 A 5/1995 Hostetler et al.

(Continued)

FOREIGN PATENT DOCUMENTS

- CA 2682230 A1 10/2008
- CN 101108870 A 1/2008

(Continued)

OTHER PUBLICATIONS

GS-7977 structure provided by Chembest Research Laboratories Ltd. (biochembest.com/product_detail.asp?m=2&id=1178&classid=65&nclassid=195). (last visit for this website was made on Jun. 27, 2013).*

World Health Organization (hereinafter 'WHO'), "Pharmaceutical excipients—an overview including considerations for paediatric dosing," (Jun. 2010).*

Gane, E., "Future Hepatitis C Virus Treatment: Interferon-Sparing Combinations," *Liver International* (2011) 31(S1): 62-67.

Gane, E., "Future Treatment for Chronic Hepatitis C: IFN or Ribavirin-Free Regimens," *Hepatology* (2012) 6:16-17 (Abstract #TCS10-03).

(Continued)

Primary Examiner — Ernst V Arnold

Assistant Examiner — Kyung Sook Chang

(74) *Attorney, Agent, or Firm* — Sheppard Mullin Richter & Hampton LLP

(57) **ABSTRACT**

Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.

(56)

References Cited

U.S. PATENT DOCUMENTS

5,420,266	A	5/1995	Britton et al.	6,777,395	B2	8/2004	Bhat et al.
5,426,183	A	6/1995	Kjell	6,784,166	B2	8/2004	Devos et al.
5,453,499	A	9/1995	Chou et al.	6,787,305	B1	9/2004	Li et al.
5,462,724	A	10/1995	Schinazi et al.	6,787,526	B1	9/2004	Bryant et al.
5,463,092	A	10/1995	Hostettler et al.	6,812,219	B2	11/2004	LaColla et al.
5,496,546	A	3/1996	Wang et al.	6,815,542	B2	11/2004	Hong et al.
5,538,848	A	7/1996	Livak et al.	6,846,810	B2	1/2005	Martin et al.
5,538,865	A	7/1996	Reyes et al.	6,897,201	B2	5/2005	Boyer et al.
5,543,389	A	8/1996	Yatvin et al.	6,908,924	B2	6/2005	Watanabe et al.
5,543,390	A	8/1996	Yatvin et al.	6,911,424	B2	6/2005	Schinazi et al.
5,543,391	A	8/1996	Yatvin et al.	6,914,054	B2	7/2005	Sommadosi et al.
5,554,728	A	9/1996	Basava et al.	6,962,991	B2	11/2005	Dempey et al.
5,610,054	A	3/1997	Draper	7,018,985	B1	3/2006	Boyer et al.
5,633,358	A	5/1997	Gruetzke et al.	7,018,989	B2	3/2006	McGuigan et al.
5,633,388	A	5/1997	Diana et al.	7,081,449	B2	7/2006	Pietrzkowski et al.
5,676,942	A	10/1997	Testa et al.	7,105,493	B2	9/2006	Sommadosi et al.
5,703,058	A	12/1997	Schinazi et al.	7,105,499	B2	9/2006	Carroll et al.
5,711,944	A	1/1998	Gilbert et al.	7,125,855	B2	10/2006	Bhat et al.
5,725,859	A	3/1998	Omer	7,148,206	B2	12/2006	Sommadosi et al.
5,738,845	A	4/1998	Imakawa	7,163,929	B2	1/2007	Sommadosi et al.
5,738,846	A	4/1998	Greenwald et al.	7,202,224	B2	4/2007	Eldrup et al.
5,747,646	A	5/1998	Hakimi et al.	7,217,523	B2	5/2007	Wagner
5,767,097	A	6/1998	Tam	7,268,119	B2	9/2007	Cook et al.
5,792,834	A	8/1998	Hakimi et al.	7,307,065	B2	12/2007	Schinazi et al.
5,830,455	A	11/1998	Valtuena et al.	7,323,453	B2	1/2008	Olsen et al.
5,830,905	A	11/1998	Diana et al.	7,365,057	B2	4/2008	LaColla et al.
5,834,594	A	11/1998	Hakimi et al.	7,390,791	B2	6/2008	Becker et al.
5,837,257	A	11/1998	Tsai et al.	7,429,572	B2	9/2008	Clark
5,846,964	A	12/1998	Ozeki	7,601,820	B2	10/2009	Wang et al.
5,849,696	A	12/1998	Chretien et al.	7,608,597	B2	10/2009	Sommadosi et al.
5,869,253	A	2/1999	Draper	7,608,600	B2	10/2009	Storer et al.
5,891,874	A	4/1999	Colacino et al.	7,635,689	B2	12/2009	LaColla et al.
5,905,070	A	5/1999	Schinazi et al.	7,754,699	B2	7/2010	Chun et al.
5,908,621	A	6/1999	Glue et al.	7,820,380	B2	10/2010	Huang
5,922,757	A	7/1999	Chojkier	7,879,815	B2	2/2011	MacCoss et al.
5,928,636	A	7/1999	Alber et al.	7,964,580	B2	6/2011	Sofia et al.
5,942,223	A	8/1999	Bazer et al.	8,148,349	B2	4/2012	Meppen et al.
5,980,884	A	11/1999	Blatt et al.	8,173,621	B2	5/2012	Du et al.
5,990,276	A	11/1999	Zhang et al.	8,334,270	B2	12/2012	Sofia et al.
6,004,933	A	12/1999	Spruce et al.	8,415,322	B2	4/2013	Clark
6,034,134	A	3/2000	Gold et al.	8,466,159	B2	6/2013	Bernstein et al.
6,043,077	A	3/2000	Barber et al.	8,551,973	B2	10/2013	Bao et al.
6,056,961	A	5/2000	Lavie et al.	8,580,765	B2	11/2013	Sofia et al.
6,060,080	A	5/2000	Kikuchi et al.	2001/0034440	A1	10/2001	Shepard et al.
6,090,932	A	7/2000	McGee et al.	2001/0038833	A1	11/2001	Rybak et al.
6,130,326	A	10/2000	Ramasamy et al.	2002/0008241	A1	1/2002	Edmond et al.
6,132,763	A	10/2000	Fisher	2002/0058635	A1	5/2002	Averett
6,156,501	A	12/2000	McGall et al.	2002/0147160	A1	10/2002	Bhat et al.
6,180,134	B1	1/2001	Zalipsky et al.	2002/0198173	A1	12/2002	Schinazi et al.
6,232,300	B1	5/2001	Schinazi et al.	2003/0050229	A1	3/2003	Sommadosi et al.
6,239,159	B1	5/2001	Brown et al.	2003/0060400	A1	3/2003	LaColla et al.
6,348,587	B1	2/2002	Schinazi et al.	2003/0096364	A1	5/2003	Baker et al.
6,372,883	B1	4/2002	Attwood et al.	2003/0119752	A1	6/2003	Farmer et al.
6,391,859	B1	5/2002	Schinazi et al.	2003/0120071	A1	6/2003	McGuigan et al.
6,410,531	B1	6/2002	Llinas-Brunet et al.	2003/0144502	A1	7/2003	Pietrzkowski et al.
6,420,380	B2	7/2002	Llinas-Brunet et al.	2003/0153744	A1	8/2003	Mekouar et al.
6,455,513	B1	9/2002	McGuigan et al.	2003/0176433	A1	9/2003	Beaulieu et al.
6,455,690	B1	9/2002	Tam et al.	2003/0187018	A1	10/2003	Llinas-Brunet et al.
6,475,985	B1	11/2002	Wagner et al.	2003/0207922	A1	11/2003	Neuner et al.
6,479,463	B1	11/2002	Wang et al.	2004/0006007	A1	1/2004	Gosselin et al.
6,495,677	B1	12/2002	Ramasamy et al.	2004/0014108	A1	1/2004	Eldrup et al.
6,509,320	B1	1/2003	Wang et al.	2004/0023240	A1	2/2004	Marliere et al.
6,534,523	B1	3/2003	Llinas-Brunet et al.	2004/0023901	A1	2/2004	Cook et al.
6,552,183	B1	4/2003	Ramasamy et al.	2004/0024190	A1	2/2004	Beaulieu et al.
6,555,677	B2	4/2003	Petrillo et al.	2004/0059104	A1	3/2004	Cook et al.
6,573,248	B2	6/2003	Ramasamy et al.	2004/0063622	A1	4/2004	Sommadosi et al.
6,642,206	B2	11/2003	Ramasamy et al.	2004/0067901	A1	4/2004	Bhat et al.
6,660,721	B2	12/2003	Devos et al.	2004/0072788	A1	4/2004	Bhat et al.
6,677,314	B2	1/2004	Klecker et al.	2004/0097461	A1	5/2004	Sommadosi et al.
6,677,315	B2	1/2004	Klecker et al.	2004/0097462	A1	5/2004	Sommadosi et al.
6,680,303	B2	1/2004	Schinazi et al.	2004/0101535	A1	5/2004	Sommadosi et al.
6,682,715	B2	1/2004	Klecker et al.	2004/0102414	A1	5/2004	Sommadosi et al.
6,683,045	B2	1/2004	Klecker et al.	2004/0110717	A1	6/2004	Carroll et al.
				2004/0142989	A1	7/2004	Finzel et al.
				2004/0142993	A1	7/2004	Battistini et al.
				2004/0167140	A1	8/2004	Schinazi et al.
				2004/0171570	A1	9/2004	Allerson et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2004/0229839 A1 11/2004 Babu et al.
 2004/0229840 A1 11/2004 Bhat et al.
 2004/0248892 A1 12/2004 Wang
 2004/0254141 A1 12/2004 Schinazi et al.
 2004/0259934 A1 12/2004 Olsen et al.
 2004/0265969 A1 12/2004 Li et al.
 2004/0266996 A1 12/2004 Rabi
 2005/0009737 A1 1/2005 Clark
 2005/0020825 A1 1/2005 Storer et al.
 2005/0026160 A1 2/2005 Allerson et al.
 2005/0026853 A1 2/2005 Mekouar et al.
 2005/0031588 A1 2/2005 Sommadossi et al.
 2005/0043390 A1 2/2005 Bravi et al.
 2005/0069522 A1 3/2005 Colonno et al.
 2005/0075309 A1 4/2005 Storer et al.
 2005/0080034 A1 4/2005 Standing et al.
 2005/0090432 A1 4/2005 McPhee et al.
 2005/0090660 A1 4/2005 Watanabe et al.
 2005/0096364 A1 5/2005 Romine et al.
 2005/0098125 A1 5/2005 Hathaway et al.
 2005/0124532 A1 6/2005 Sommadossi et al.
 2005/0130923 A1 6/2005 Bhat et al.
 2005/0130931 A1 6/2005 Boyer et al.
 2005/0137161 A1 6/2005 Sommadossi et al.
 2005/0148534 A1 7/2005 Castellino et al.
 2005/0154056 A1 7/2005 Yang et al.
 2005/0164960 A1 7/2005 Olsen et al.
 2005/0215513 A1 9/2005 Boojamra et al.
 2005/0215614 A1 9/2005 Singh et al.
 2005/0227947 A1 10/2005 Chen et al.
 2005/0228013 A1 10/2005 Thurkauf et al.
 2005/0261237 A1 11/2005 Boojamra et al.
 2005/0267018 A1 12/2005 Blatt et al.
 2006/0003951 A1 1/2006 Mekouar et al.
 2006/0004063 A1 1/2006 Finzel et al.
 2006/0014943 A1 1/2006 Dempcy et al.
 2006/0035866 A1 2/2006 Cannizzaro et al.
 2006/0040890 A1 2/2006 Martin et al.
 2006/0040927 A1 2/2006 Blake et al.
 2006/0040944 A1 2/2006 Gosselin et al.
 2006/0046983 A1 3/2006 Hudyma et al.
 2006/0079478 A1 4/2006 Boojamra et al.
 2006/0094706 A1 5/2006 Paruch et al.
 2006/0110724 A1 5/2006 Burkhardt, III et al.
 2006/0110727 A9 5/2006 McGall et al.
 2006/0122146 A1 6/2006 Chun et al.
 2006/0122154 A1 6/2006 Olsen et al.
 2006/0142238 A1 6/2006 McGuigan
 2006/0166964 A1 7/2006 Hudyma et al.
 2006/0194749 A1 8/2006 Keicher et al.
 2006/0199783 A1 9/2006 Wang et al.
 2006/0234962 A1 10/2006 Olsen et al.
 2006/0241064 A1 10/2006 Roberts et al.
 2006/0276405 A1 12/2006 Albrecht
 2006/0276511 A1 12/2006 Serrano-Wu et al.
 2006/0287300 A1 12/2006 Klein et al.
 2006/0293306 A1 12/2006 Beaulieu et al.
 2007/0004669 A1 1/2007 Carroll et al.
 2007/0015905 A1 1/2007 LaColla et al.
 2007/0024277 A1 2/2007 Cech et al.
 2007/0037735 A1 2/2007 Gosselin et al.
 2007/0037773 A1 2/2007 Sommadossi et al.
 2007/0042939 A1 2/2007 LaColla et al.
 2007/0042988 A1 2/2007 Klumpp et al.
 2007/0042990 A1 2/2007 Gosselin et al.
 2007/0049754 A1 3/2007 Boojamra et al.
 2007/0054842 A1 3/2007 Blatt et al.
 2007/0060498 A1 3/2007 Gosselin et al.
 2007/0060541 A1 3/2007 Gosselin et al.
 2007/0087960 A1 4/2007 Storer et al.
 2007/0123484 A1 5/2007 Bhat et al.
 2007/0135363 A1 6/2007 Cook et al.
 2007/0142380 A1 6/2007 Beaulieu et al.

2007/0197478 A1 8/2007 Jones et al.
 2007/0225249 A1 9/2007 Shi
 2007/0231318 A1 10/2007 Saha et al.
 2007/0232627 A1 10/2007 Betebenner et al.
 2007/0232645 A1 10/2007 Rockway et al.
 2007/0265222 A1 11/2007 MacCoss et al.
 2007/0265262 A1 11/2007 Schmitz et al.
 2007/0274947 A1 11/2007 Young et al.
 2007/0275912 A1 11/2007 Bhat et al.
 2007/0275930 A1 11/2007 Gentles et al.
 2007/0275947 A1 11/2007 Bergstrom
 2008/0021047 A1 1/2008 Butora et al.
 2008/0050336 A1 2/2008 Bachand et al.
 2008/0070861 A1 3/2008 Clark
 2008/0108617 A1 5/2008 Desai et al.
 2008/0146788 A1 6/2008 Bhat et al.
 2008/0182863 A1 7/2008 Simmen et al.
 2008/0253995 A1 10/2008 Clark
 2008/0280842 A1 11/2008 MacCoss et al.
 2009/0004135 A1 1/2009 Clark
 2009/0036666 A1 2/2009 Clark
 2009/0041716 A1 2/2009 Kim et al.
 2009/0062311 A1 3/2009 Simmen et al.
 2009/0105302 A1 4/2009 Simmen et al.
 2009/0137521 A1 5/2009 Hamilton et al.
 2009/0156595 A1 6/2009 Raboisson et al.
 2009/0176732 A1 7/2009 Beigelman et al.
 2009/0233879 A1 9/2009 Reddy et al.
 2009/0269305 A1 10/2009 Seiwert et al.
 2009/0280084 A1 11/2009 Schinazi et al.
 2009/0281140 A1 11/2009 Simmen et al.
 2009/0281141 A1 11/2009 Simmen et al.
 2009/0291902 A1 11/2009 Cottrell et al.
 2009/0306007 A1 12/2009 Wagner
 2010/0015090 A1 1/2010 Tung et al.
 2010/0016251 A1 1/2010 Sofia et al.
 2010/0022468 A1 1/2010 Meppen et al.
 2010/0029008 A1 2/2010 Rojas Stutz et al.
 2010/0035835 A1 2/2010 Narjes et al.
 2010/0081628 A1 4/2010 Du et al.
 2010/0137576 A1 6/2010 Stec et al.
 2010/0152128 A1 6/2010 Attenni et al.
 2010/0173863 A1 7/2010 Schinazi et al.
 2010/0226885 A1 9/2010 Albrecht et al.
 2010/0227801 A1 9/2010 Hopkins
 2010/0234316 A1 9/2010 MacCoss et al.
 2010/0267785 A1 10/2010 Wu et al.
 2010/0279973 A1 11/2010 Chun et al.
 2010/0286083 A1 11/2010 Bao et al.
 2010/0298257 A1 11/2010 Ross et al.
 2010/0316594 A1 12/2010 Sommadossi et al.
 2011/0015146 A1 1/2011 Sofia et al.
 2011/0020272 A1* 1/2011 Schubert 424/85.2
 2011/0124592 A1 5/2011 McGuigan et al.
 2011/0237621 A1 9/2011 Simmen et al.
 2011/0245484 A1 10/2011 Ross et al.
 2011/0251152 A1 10/2011 Ross et al.
 2011/0257122 A1 10/2011 Sofia et al.
 2012/0094284 A1 4/2012 Lopatin et al.
 2012/0107278 A1 5/2012 Berrey et al.
 2012/0245335 A1 9/2012 Clark
 2012/0251152 A1 10/2012 Brewington et al.
 2013/0029929 A1 1/2013 Sofia et al.
 2013/0102526 A1 4/2013 Bernstein et al.
 2013/0102557 A1 4/2013 Bernstein et al.
 2013/0102558 A1 4/2013 Bernstein et al.
 2013/0109647 A1 5/2013 Berrey et al.
 2013/0136776 A1 5/2013 Cleary et al.
 2013/0137654 A1 5/2013 Ross et al.
 2013/0165401 A1 6/2013 Ross et al.
 2013/0165644 A1 6/2013 Ross et al.
 2013/0288997 A1 10/2013 Ross et al.
 2013/0310551 A1 11/2013 Ross et al.

FOREIGN PATENT DOCUMENTS

DE 199 14 474 A1 10/1999

(56)

References Cited

FOREIGN PATENT DOCUMENTS

EP 0 350 287 A2 1/1990
 EP 1 828 217 A2 9/2007
 EP 1 881 001 A1 1/2008
 EP 2 097 430 A1 9/2009
 EP 2 124 555 A2 12/2009
 EP 2 207 786 B1 3/2012
 JP 5-238939 A 9/1993
 WO 89/02733 A1 4/1989
 WO 90/00555 A1 1/1990
 WO 91/16920 A1 11/1991
 WO 91/18914 A1 12/1991
 WO 91/19721 A1 12/1991
 WO 93/00910 A1 1/1993
 WO 94/26273 A1 11/1994
 WO 95/13090 A1 5/1995
 WO 95/24185 A1 9/1995
 WO 96/15132 A1 5/1996
 WO 96/32403 A2 10/1996
 WO 97/12033 A1 4/1997
 WO 97/36554 A1 10/1997
 WO 98/16184 A2 4/1998
 WO 98/17679 A1 4/1998
 WO 98/22496 A2 5/1998
 WO 99/07734 A2 2/1999
 WO 99/15194 A1 4/1999
 WO 99/32139 A1 7/1999
 WO 99/32140 A1 7/1999
 WO 99/43691 A1 9/1999
 WO 99/59621 A1 11/1999
 WO 99/64016 A1 12/1999
 WO 00/06529 A1 2/2000
 WO 00/09531 A2 2/2000
 WO 00/37110 A2 6/2000
 WO 01/09121 A2 2/2001
 WO 01/32153 A2 5/2001
 WO 01/60315 A2 8/2001
 WO 01/79246 A2 10/2001
 WO 01/81359 A1 11/2001
 WO 01/90121 A2 11/2001
 WO 01/91737 A2 12/2001
 WO 01/92282 A2 12/2001
 WO 01/96353 A2 12/2001
 WO 02/08187 A1 1/2002
 WO 02/08198 A2 1/2002
 WO 02/08251 A2 1/2002
 WO 02/08256 A2 1/2002
 WO 02/18404 A2 3/2002
 WO 02/32414 A2 4/2002
 WO 02/32920 A2 4/2002
 WO 02/48116 A2 6/2002
 WO 02/48157 A2 6/2002
 WO 02/48165 A2 6/2002
 WO 02/48172 A2 6/2002
 WO 02/057287 A2 7/2002
 WO 02/057425 A2 7/2002
 WO 02/060926 A2 8/2002
 WO 02/100415 A2 12/2002
 WO 03/000713 A1 1/2003
 WO 03/006490 A1 1/2003
 WO 03/010141 A2 2/2003
 WO 03/024461 A1 3/2003
 WO 03/026589 A2 4/2003
 WO 03/037895 A1 5/2003
 WO 03/051899 A1 6/2003
 WO 03/053989 A1 7/2003
 WO 03/061576 A2 7/2003
 WO 03/062256 A1 7/2003
 WO 03/064456 A1 8/2003
 WO 03/068244 A1 8/2003
 WO 03/101993 A1 12/2003
 WO 03/104250 A1 12/2003
 WO 03/105770 A2 12/2003
 WO 03/106477 A1 12/2003

WO 2004/002940 A1 1/2004
 WO 2004/002944 A1 1/2004
 WO 2004/002977 A1 1/2004
 WO 2004/002999 A2 1/2004
 WO 2004/003000 A2 1/2004
 WO 2004/003138 A2 1/2004
 WO 2004/007512 A2 1/2004
 WO 2004/009020 A2 1/2004
 WO 2004/009610 A2 1/2004
 WO 2004/011478 A2 2/2004
 WO 2004/014313 A2 2/2004
 WO 2004/014852 A2 2/2004
 WO 2004/035571 A1 4/2004
 WO 2004/041201 A2 5/2004
 WO 2004/046331 A2 6/2004
 WO 2004/065367 A1 8/2004
 WO 2004/080466 A1 9/2004
 WO 2004/094452 A2 11/2004
 WO 2004/096210 A1 11/2004
 WO 2004/096234 A2 11/2004
 WO 2004/096235 A2 11/2004
 WO 2004/096286 A2 11/2004
 WO 2004/096210 A1 11/2004
 WO 2004/106356 A1 12/2004
 WO 2005/002626 A2 1/2005
 WO 2005/003147 A2 1/2005
 WO 2005/003147 A2 1/2005
 WO 2005/007810 A2 1/2005
 WO 2005/009418 A2 2/2005
 WO 2005/012327 A2 2/2005
 WO 2005/020884 A2 3/2005
 WO 2005/021568 A2 3/2005
 WO 2005/028502 A1 3/2005
 WO 2005/037214 A2 4/2005
 WO 2005/067900 A2 7/2005
 WO 2005/072361 A2 8/2005
 WO 2005/082144 A1 9/2005
 WO 2005/087788 A2 9/2005
 WO 2005/095403 A2 10/2005
 WO 2005/103045 A1 11/2005
 WO 2005/103045 A1 11/2005
 WO 2005/123087 A2 12/2005
 WO 2006/000922 A2 1/2006
 WO 2006/012078 A2 2/2006
 WO 2006/012440 A2 2/2006
 WO 2006/020082 A1 2/2006
 WO 2006/029081 A2 3/2006
 WO 2006/031725 A2 3/2006
 WO 2006/035061 A1 4/2006
 WO 2006/037028 A2 4/2006
 WO 2006/050161 A2 5/2006
 WO 2006/063149 A1 6/2006
 WO 2006/063717 A2 6/2006
 WO 2006/065335 A2 6/2006
 WO 2006/065590 A2 6/2006
 WO 2006/067606 A1 6/2006
 WO 2006/065590 A2 6/2006
 WO 2006/093801 A1 9/2006
 WO 2006/100310 A1 9/2006
 WO 2006/116557 A1 11/2006
 WO 2006/120251 A1 11/2006
 WO 2006/120252 A2 11/2006
 WO 2006/121820 A1 11/2006
 WO 2007/002602 A2 1/2007
 WO 2007/014920 A1 2/2007
 WO 2007/014921 A1 2/2007
 WO 2007/014922 A1 2/2007
 WO 2007/014925 A1 2/2007
 WO 2007/014926 A1 2/2007
 WO 2007/015824 A2 2/2007
 WO 2007/020193 A2 2/2007
 WO 2007/027248 A2 3/2007
 WO 2007/039142 A1 4/2007
 WO 2007/039145 A1 4/2007
 WO 2007/039142 A1 4/2007
 WO 2007/039145 A1 4/2007
 WO 2007/065829 A1 6/2007

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	2007/088148	A1	8/2007
WO	2007/092000	A1	8/2007
WO	2007/093901	A1	8/2007
WO	2007/095269	A2	8/2007
WO	2007088148	A1	8/2007
WO	2007092000	A1	8/2007
WO	2008/010921	A2	1/2008
WO	2008/045419	A1	4/2008
WO	2008/048128	A1	4/2008
WO	2008/062206	A2	5/2008
WO	2008/079206	A1	7/2008
WO	2008/082601	A2	7/2008
WO	2008/085508	A2	7/2008
WO	2008121634	A2	10/2008
WO	2008/142055	A2	11/2008
WO	2009/029844	A1	3/2009
WO	2009038663	A1	3/2009
WO	2009/052287	A1	4/2009
WO	2009/115893	A2	9/2009
WO	2009/120878	A2	10/2009
WO	2009/129120	A2	10/2009
WO	2009/132123	A1	10/2009
WO	2009/152095	A2	12/2009
WO	2010/042834	A1	4/2010
WO	2010/075517	A2	7/2010
WO	2010/075549	A2	7/2010
WO	2010/075554	A1	7/2010
WO	2010/080878	A1	7/2010
WO	2010/081082	A2	7/2010
WO	2010075517	A2	7/2010
WO	2010112203	A1	10/2010
WO	2010135569	A1	11/2010
WO	2011/035231	A1	3/2011
WO	2011123645	A2	10/2011
WO	2011123672	A1	10/2011
WO	2012/130862	A1	10/2012
WO	2013059630	A1	4/2013
WO	2013059638	A1	4/2013

OTHER PUBLICATIONS

Gane, E. et al., "Once Daily GS-7977 Plus Ribavirin in HCV Genotypes 1-3: The Electron Trial," EASL 47th Annual Meeting, Barcelona, Spain (Apr. 18-22, 2012).

Poordad, F. et al., "A 12-Week Interferon-Free Regimen of ABT-4501r+ABT-333+Ribavirin Achieved SVR12 in More Than 90% of Treatment-Naive HCV Genotype-1-Infected Subjects and 47% of Previous Non-Responders," EASL 47th Annual Meeting, Barcelona, Spain (Apr. 18-22, 2012).

Lewis, H., et al., "Second Generation Direct Antiviral and the Way to Interferon-Free Regimens in Chronic HCV," Best Practices & Research: Clinical Gastroenterology (2012) 26:471-485.

Lawitz, E., et al., "The Effect of Hepatic Impairment on the Safety, Pharmacokinetics, and Antiviral Activity of GS-7977 in Hepatitis C Infected Subjects Treated for Seven Days," Presented at the 47th Annual Meeting of the European Association for the Study of the Liver (Apr. 18-22, 2012), Barcelona, Spain (Poster #1130).

Zhu, Y., et al., "Virologic Analysis of HCV Genotype 1 Patient Samples from the Proton Study," Presented at the 47th Annual Meeting of the European Association for the Study of the Liver (Apr. 18-22, 2012), Barcelona, Spain (Poster #1217).

Gane, E., et al., "Once Daily GS-7977 Plus Ribavirin in HCV Genotypes 1-3: The Electron Trial," Presented at the 47th Annual Meeting of the European Association for the Study of the Liver (Apr. 18-22, 2012), Barcelona, Spain (Poster #1113).

Jacobson, I., "GS-7977 400 mg QD Safety and Tolerability in the Over 500 Patients Treated for at Least 12 Weeks," Presented at the 47th Annual Meeting of the European Association for the Study of the Liver (Apr. 18-22, 2012), Barcelona, Spain (Poster #1120).

Presented at the 47th Annual Meeting of the European Association for the Study of the Liver (Apr. 18-22, 2012), Barcelona, Spain (Poster #1101).

Afdhal et al., *Hepatology* (2011) 53(1): 336-345.

Asselah et al., *Gut* (2009) 58: 846-858.

Asselah et al., *J. Hepatology* (2012) 56: 527-532.

Clark et al., *Bioorg. Med. Chem. Lett.* (2006) 16: 1712-1715.

Clark et al., *J. Med. Chem.* (2005) 48: 5504-5508.

Cotton et al., *Mutat. Res.* 285:125-144 (1993).

Dienstag and McHutchison *Gastroenterology* 2006; 130: 231-264.

F. Ruebasam et al., *Bio. Org. Med. Chem. Lett.* (2008) 18: 3616-3621.

Ge et al., *Nature* (2009) 461(17): 399-401.

Hayashi et al., *Genet. Anal. Techn. App* 9: 73-79 (1992).

K. Ishi et al., *Heptology*, 1999, 29: 1227-1235.

Kwo et al., *Lancet* 2010; 376 (9742): 705-716.

Lalezari et al., *J. Hepatology* (2011) 54: S28. (Abstract 61).

Lindh et al., *J. Infect. Dis.* (2011) 203: 1748-1752.

Mangia et al., *Gastroenterology* (2010) 139: 821-827.

McCarthy et al., *Gastroenterology* (2010) 138: 2307-2314.

Moghaddam et al., *Hepatology* (2011) 53(3): 746-754.

Rauch et al., *Gastroenterology* (2010) 138: 1338-1345.

Sarrazin et al., *J. Hepatology* (2011) 54: 415-421.

Suppiah et al., *Nature Genetics* (2009) 41(10): 1100-1104.

Tanaka et al., *Nature Genetics* (2009) 41(10): 1105-1109.

Von Wagner et al., *Gastroenterology* (2005) 129: 522-527.

Stuyver et al., *Antiviral Chem. & Chemother.* (2006) 17: 79-87.

Sofia et al., *J. Med. Chem.* (2010) 53(19): 7202-7218.

Sofia, *Antiviral Chem. & Chemother.* (2011) 22: 23-49.

Paul J. Pockros et al., *Hepatology* (2008) 48(2): 385-397.

U.S. Appl. No. 13/099,671, filed May 3, 2011—Claims as Amended Sep. 4, 2012.

U.S. Appl. No. 11/854,218, filed Sep. 12, 2007—Claims as Amended Jun. 28, 2011.

U.S. Appl. No. 12/878,262, filed Sep. 9, 2010—Claims as Amended Sep. 1, 2011.

Rodriguez-Torres et al., *Hepatology* (2009) 50(6): 11A (Abstract LB17).

Nelson et al., *J. Hepatology* (2011), vol. 54, pp. S544 (Abstract #1372).

Missiha, S.B., et al., "Disease Progression in Chronic Hepatitis C: Modifiable and Nonmodifiable Factors," *Gastroenterology* (2008), vol. 134, pp. 1699-1714.

Zeuzem, S., et al., "Review article: management of patients with chronic hepatitis C virus infection and 'normal' alanine aminotransferase activity," *Aliment Pharmacol. & Ther.* (2006), Vol. 24, pp. 1133-1149.

Orita, M., et al., "Detection of polymorphisms of DNA by gel electrophoresis as single-strand conformation polymorphisms," *Proc. Natl. Acad. Sci. USA* (1989), vol. 86, pp. 2766-2770.

Poordad, F., et al., "Rapid Virologic Response: A New Milestone in the Management of Chronic Hepatitis C," *Clin. Infectious Diseases* (2008), Vol. 46, pp. 78-84.

Myers, R.M., et al., "Detection of single base substitutions in total genomic DNA," *Nature* (1985) vol. 313, pp. 495-498.

Saleeba, J.A., et al., "Chemical Cleavage of Mismatch to Detect Mutations," *Mutagenesis and Gene Disruption* (1993), vol. 217, 286-295.

Stephens, J.C., et al., "Haplotype Variation and Linkage Disequilibrium in 313 Human Genes," *Science* (2001), vol. 293, pp. 489-493.

McHutchison, J.G., et al., "Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection," *N. Engl. J. Med.* (2009), vol. 360, No. 18, pp. 1827-1838.

Mitchell et al., "Bioreversible Protection for the Phospho Group: Bioactivation of the Di(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Phosphoesters of Methylphosphonate and Phosphonoacetate," *J. Chem. Soc. Perkin. Trans. 1*, pp. 2345-2353 (1992).

Olsen et al., "2'-Modified Nucleoside Analogs as Inhibitors of Hepatitis C RNA Replication," Program and Abstracts, 16th International

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.